Per the 2019 version of Management of Hyperglycemia in Type 2 Diabetes, a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes, SGLT2i or GLP-1 RAs can be started in the appropriate high-risk individuals with established type 2 diabetes to decrease heart failure hospitalization, major adverse cardiovascular events (MACE), cardiovascular (CV) death, or CKD progression independent of baseline hemoglobin A1c (Hba1c) [41]. The gene discussed is GLP1R; the disease is diabetes mellitus.